Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
about
Phosphodiesterase 4-targeted treatments for autoimmune diseasesT cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitorsSynthesis, Structural Analysis, and Biological Evaluation of Thioxoquinazoline Derivatives as Phosphodiesterase 7 InhibitorsModulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzymePDE 7 inhibitors: new potential drugs for the therapy of spinal cord injuryDrug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.Caboxamycin, a new antibiotic of the benzoxazole family produced by the deep-sea strain Streptomyces sp. NTK 937.Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.Effects of inactivated Bordetella pertussis on phosphodiesterase in the lung of ovalbumin sensitized and challenged rats.Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia.ABCD of the phosphodiesterase family: interaction and differential activity in COPDApremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases.Phosphodiesterase isoform-specific expression induced by traumatic brain injury.Emerging drugs for the treatment of chronic obstructive pulmonary disease.Identification of a potent new chemotype for the selective inhibition of PDE4Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment.Pharmacological treatment of chronic obstructive pulmonary disease.Treating COPD with PDE 4 inhibitors.Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.DISC1 as a therapeutic target for mental illnesses.Developments in drugs for the treatment of chronic obstructive pulmonary disease.Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders.Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012).Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.Apremilast for the treatment of psoriatic arthritis.Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.TGF-beta1 stimulates monocyte chemoattractant protein-1 expression in mesangial cells through a phosphodiesterase isoenzyme 4-dependent process.Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases.Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.Differential regulation of mesangial cell mitogenesis by cAMP phosphodiesterase isozymes 3 and 4.Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers.Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap
P2860
Q21245284-EA058194-0D53-456F-82FC-52119590B096Q24627662-12DC1C08-0E43-4C74-AFCA-AB98993FC7B6Q27647620-F9E6DEF0-80BA-4963-A824-54A5394FC446Q27654567-5719358D-B529-45D4-BE4A-5B006DC0C27FQ28357383-6E74EB94-9E7D-47E4-ABDB-9C731FD19F23Q28477025-23188F06-B83B-4164-9818-4F8DB4EDE701Q30249747-D0943812-2E1C-4129-A579-C666DD8FFD05Q33406492-5A55223E-4DCC-45DE-BEEB-22492D9CEB69Q33895012-AE0D535C-F400-4E16-8955-196B4295AECAQ33998876-40EE47E3-739F-45A5-9A09-028453CAD703Q34481601-30E04603-19CC-4293-BC90-183DFD24462FQ34500909-4B7B5515-536B-47F7-BDB5-E3CBE995530EQ34961511-5BD0C01E-345C-4937-98B3-37364360093FQ36061710-FDD049A6-8F34-4512-8E9D-C02DC4AC9330Q36165890-61F171EC-3EAF-4740-AB90-D7229783D6F8Q36446011-0008BA2F-1468-458F-BF67-456E0E750DF5Q36458412-01702CF0-8430-459E-A806-560BF69A7F66Q36499703-C78DF736-2AB0-4995-90CA-80488B19A179Q36792648-DFBA4FE1-86DA-48C6-A655-669EBCA1C508Q37017344-D956396D-BEE7-4244-9489-BC2EE1BF31DFQ37082594-E93AE8AC-1A9C-44C6-A553-2F20DB995F1BQ37332621-5EA3DDA7-8F29-4DF4-968B-0393F17D87DDQ37698116-3CDB18A2-31AA-4BD4-A094-DD184D6E569AQ37754541-9687ACC3-CD52-41BC-99FF-7F18E27EA50FQ37947681-8EAAE6D5-1646-411B-AFB8-89F1D8F180D7Q38097492-684B35C8-6C47-42E6-9785-BEBBA6BEE09AQ38103909-EAC50827-EAE2-40BD-B5BD-455DD5829EBFQ38187182-FB7632FA-0508-4DF7-8936-BBF4949D8C7EQ38202205-5E0EE972-3C71-4ED5-84FD-4DA2CA565586Q38243490-D9BAFC2F-D79F-4A73-9F9A-68565784496CQ40414618-B52E425E-9AB4-4E1B-9242-5CFF832A839EQ41771251-ACF8649C-837F-45D8-9EDE-A65E9B14E198Q43061572-441A19E5-4817-419A-BB7C-435DC2DCA444Q44997546-3228F364-B175-45E5-9D3B-70912636836BQ47872223-14FD7186-9A85-4FCB-9A8B-BE39BEB79715Q58806313-588A1F9D-D400-4AB1-8588-E35532B0A568
P2860
Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Suppression of human inflammat ...... inhibition of PDE4A and PDE4B.
@en
Suppression of human inflammat ...... inhibition of PDE4A and PDE4B.
@nl
type
label
Suppression of human inflammat ...... inhibition of PDE4A and PDE4B.
@en
Suppression of human inflammat ...... inhibition of PDE4A and PDE4B.
@nl
prefLabel
Suppression of human inflammat ...... inhibition of PDE4A and PDE4B.
@en
Suppression of human inflammat ...... inhibition of PDE4A and PDE4B.
@nl
P2093
P2860
P356
P1476
Suppression of human inflammat ...... inhibition of PDE4A and PDE4B.
@en
P2093
Barnette MS
Christensen SB
Cieslinski LB
Essayan DM
Manning CD
P2860
P304
P356
10.1038/SJ.BJP.0702911
P407
P577
1999-12-01T00:00:00Z